Loading clinical trials...
Loading clinical trials...
An Open-label Randomized Controlled Trial on Lopinavir/ Ritonavir, Ribavirin and Interferon Beta 1b Combination Versus Lopinavir/ Ritonavir Alone, as Treatment for 2019 Novel Coronavirus Infection
Conditions
Interventions
Lopinavir/ritonavir
Ribavirin
+1 more
Locations
1
Hong Kong
University of Hong Kong, Queen Mary Hospital
Hong Kong, Hong Kong
Start Date
February 10, 2020
Primary Completion Date
March 30, 2020
Completion Date
March 31, 2020
Last Updated
April 15, 2020
NCT04610515
NCT05375773
NCT04470583
Lead Sponsor
The University of Hong Kong
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions